1. TALENs Targeting HBV: Designer Endonuclease Therapies for Viral Infections 
Nicholas D Weber, Daniel Stone, Keith R Jerome 
Molecular Therapy 
Volume 21, Issue 10, Pages (October 2013)
DOI: /mt
Copyright © 2013 The American Society of Gene & Cell Therapy Terms and Conditions

2. Figure 1
Inhibition of HBV replication. Currently approved antivirals include reverse transcriptase inhibitors (RTi) and the immune system modulator interferon-α2a. Covalently closed circular DNA (cccDNA) is not affected by these antiviral drugs and remains in the nucleus throughout the lifetime of an infected cell. Targeted endonucleases promote disruption of cccDNA, which prevents viral replication by blocking expression of functional viral proteins. CRISPR, clustered regularly interspaced short palindromic repeats; ER, endoplasmic reticulum; HBcAg, hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HE, homing endonuclease; pgRNA, pregenomic RNA; rcDNA, relaxed circular DNA; TALEN, transcription activator–like effector nuclease; ZFN, zinc-finger nuclease.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2013 The American Society of Gene & Cell Therapy Terms and Conditions